Overview of clinically approved oral antidiabetic agents for the treatment of type 2 diabetes mellitus

Clinical and Experimental Pharmacology and Physiology

Volumn 42, Issue 2, 2015, Pages 125-138

  He, Zhi Xu ^a   Zhou, Zhi Wei ^b   Yang, Yinxue ^c   Yang, Tianxin ^d   Pan, Si Yuan ^e   Qiu, Jia Xuan ^f   Zhou, Shu Feng ^b  

^a GUIZHOU MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c NINGXIA MEDICAL UNIVERSITY   (China)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e BEIJING UNIVERSITY OF CHINESE MEDICINE   (China)

^f NANCHANG UNIVERSITY   (China)

Author keywords

Biguanide; Dipeptidyl peptidase 4; Metformin; Sulphonylurea; Type 2 diabetes mellitus

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALDOSE REDUCTASE INHIBITOR; ALPHA GLUCOSIDASE INHIBITOR; AMYLIN RECEPTOR AGONIST; ANOREXIGENIC AGENT; BIGUANIDE DERIVATIVE; BROMOCRIPTINE; DOPAMINE 2 RECEPTOR STIMULATING AGENT; G PROTEIN COUPLED RECEPTOR; GLITAZAR DERIVATIVE; GLITAZONE DERIVATIVE; GLUCOSIDASE; METFORMIN; ORAL ANTIDIABETIC AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PROTEIN SERINE THREONINE KINASE; SODIUM GLUCOSE COTRANSPORTER INHIBITOR; SULFONYLUREA DERIVATIVE; TRANSCRIPTION FACTOR; VOLTAGE GATED POTASSIUM CHANNEL; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL;

ANTIDIABETIC ACTIVITY; ARTICLE; DRUG EFFECT; DRUG MECHANISM; GLUCOSE BLOOD LEVEL; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; DIABETES MELLITUS, TYPE 2; METABOLISM;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS;

EID: 84920870211     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/1440-1681.12332     Document Type: Article

References (100)

1. Holman RR. Type 2 diabetes mellitus in 2012. Optimal management of T2DM remains elusive. Nat. Rev. Endocrinol. 2013; 9: 67-8.
2. Stein SA, Lamos EM, Davis SN. A review of the efficacy and safety of oral antidiabetic drugs. Expert Opin. Drug Saf. 2013; 12: 153-75.
3. Oka M, Kato N. Aldose reductase inhibitors. J. Enzyme Inhib. 2001; 16: 465-73.
4. Sestanj K, Bellini F, Fung S et al. N-[5-(Trifluoromethyl)-6-methoxy-1-naphthalenyl]thioxomethyl]-N-methylglycine (tolrestat), a potent, orally active aldose reductase inhibitor. J. Med. Chem. 1984; 27: 255-6.
5. Foppiano M, Lombardo G. Worldwide pharmacovigilance systems and tolrestat withdrawal. Lancet 1997; 349: 399-400.
6. Nyholm B, Brock B, Orskov L, Schmitz O. Amylin receptor agonists: A novel pharmacological approach in the management of insulin-treated diabetes mellitus. Expert Opin. Investig. Drugs 2001; 10: 1641-52.
7. Scheen AJ. DPP-4 inhibitors in the management of type 2 diabetes: A critical review of head-to-head trials. Diabetes Metab. 2012; 38: 89-101.
8. Plosker GL. Dapagliflozin: A review of its use in type 2 diabetes mellitus. Drugs 2012; 72: 2289-312.
9. Deeks ED. Linagliptin. A review of its use in the management of type 2 diabetes mellitus. Drugs 2012; 72: 1793-824.
10. Gong L, Goswami S, Giacomini KM, Altman RB, Klein TE. Metformin pathways: Pharmacokinetics and pharmacodynamics. Pharmacogenet. Genomics 2012; 22: 820-7.
11. Inkster B, Zammitt NN, Frier BM. Drug-induced hypoglycaemia in type 2 diabetes. Expert Opin. Drug Saf. 2012; 11: 597-614.
12. Gough SC. Liraglutide: From clinical trials to clinical practice. Diabetes Obes. Metab. 2012; 14 (Suppl. 2): 33-40.
13. Pillay K, Govender P. Amylin uncovered: A review on the polypeptide responsible for type II diabetes. Biomed. Res. Int. 2013; 2013: 826706.
14. Lebovitz HE. Adjunct therapy for type 1 diabetes mellitus. Nat. Rev. Endocrinol. 2010; 6: 326-34.
15. Kleppinger EL, Vivian EM. Pramlintide for the treatment of diabetes mellitus. Ann. Pharmacother. 2003; 37: 1082-9.
16. Younk LM, Mikeladze M, Davis SN. Pramlintide and the treatment of diabetes: A review of the data since its introduction. Expert Opin. Pharmacother. 2011; 12: 1439-51.
17. Kohl C, Ravel D, Girard J, Pegorier JP. Effects of benfluorex on fatty acid and glucose metabolism in isolated rat hepatocytes: From metabolic fluxes to gene expression. Diabetes 2002; 51: 2363-8.
18. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-65.
19. Mehanna A. Antidiabetic agents: Past, present and future. Future Med. Chem. 2013; 5: 411-30.
20. Miller RA, Chu Q, Xie J, Foretz M, Viollet B, Birnbaum MJ. Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP. Nature 2013; 494: 256-60.
21. Viollet B, Guigas B, Sanz Garcia N, Leclerc J, Foretz M, Andreelli F. Cellular and molecular mechanisms of metformin: An overview. Clin. Sci. 2012; 122: 253-70.
22. Cabreiro F, Au C, Leung KY et al. Metformin retards aging in C. elegans by altering microbial folate and methionine metabolism. Cell 2013; 153: 228-39.
23. Robert F, Fendri S, Hary L, Lacroix C, Andrejak M, Lalau JD. Kinetics of plasma and erythrocyte metformin after acute administration in healthy subjects. Diabetes Metab. 2003; 29: 279-83.
24. Out C, Groen AK, Brufau G. Bile acid sequestrants: More than simple resins. Curr. Opin. Lipidol. 2012; 23: 43-55.
25. Takebayashi K, Aso Y, Inukai T. Role of bile acid sequestrants in the treatment of type 2 diabetes. World J. Diabetes 2010; 1: 146-52.
26. Emami Riedmaier A, Fisel P, Nies AT, Schaeffeler E, Schwab M. Metformin and cancer. From the old medicine cabinet to pharmacological pitfalls and prospects. Trends Pharmacol. Sci. 2013; 34: 126-35.
27. Hemmingsen B, Christensen LL, Wetterslev J et al. Comparison of metformin and insulin versus insulin alone for type 2 diabetes. Systematic review of randomised clinical trials with meta-analyses and trial sequential analyses. BMJ 2012; 344: e1771.
28. Edwards KL, Stapleton M, Weis J, Irons BK. An update in incretin-based therapy. A focus on glucagon-like peptide-1 receptor agonists. Diabetes Technol. Ther. 2012; 14: 951-67.
29. Stonehouse AH, Darsow T, Maggs DG. Incretin-based therapies. J. Diabetes 2012; 4: 55-67.
30. Dailey MJ, Moran TH. Glucagon-like peptide 1 and appetite. Trends Endocrinol. Metab. 2013; 24: 85-91.
31. Russell S. Incretin-based therapies for type 2 diabetes mellitus: A review of direct comparisons of efficacy, safety and patient satisfaction. Int. J. Clin. Pharm. 2013; 35: 159-72.
32. Subbarayan S, Kipnes M. Sitagliptin: A review. Expert Opin. Pharmacother. 2011; 12: 1613-22.
33. Holt RI, Barnett AH, Bailey CJ. Bromocriptine: Old drug, new formulation and new indication. Diabetes Obes. Metab. 2010; 12: 1048-57.
34. Pijl H, Edo AM. Modulation of monoaminergic neural circuits. Potential for the treatment of type 2 diabetes mellitus. Treat. Endocrinol. 2002; 1: 71-8.
35. 2-adrenergic receptors in β-cells. Biochem. Pharmacol. 2010; 79: 1827-36.
36. Derosa G, Maffioli P. α-Glucosidase inhibitors and their use in clinical practice. Arch. Med. Sci. 2012; 8: 899-906.
37. Nathan DM, Buse JB, Davidson MB et al. Medical management of hyperglycaemia in type 2 diabetes mellitus. A consensus algorithm for the initiation and adjustment of therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2009; 52: 17-30.
38. Narender T, Madhur G, Jaiswal N et al. Synthesis of novel triterpene and N-allylated/N-alkylated niacin hybrids as alpha-glucosidase inhibitors. Eur. J. Med. Chem. 2013; 63: 162-9.
39. Nauck M, Horton E, Andjelkovic M et al. Taspoglutide, a once-weekly glucagon-like peptide 1 analogue, vs. insulin glargine titrated to target in patients with Type 2 diabetes: An open-label randomized trial. Diabet. Med. 2013; 30: 109-13.
40. Black C, Donnelly P, McIntyre L, Royle PL, Shepherd JP, Thomas S. Meglitinide analogues for type 2 diabetes mellitus. Cochrane Database Syst. Rev. 2007; 2: CD004654.
41. Scott LJ. Repaglinide: A review of its use in type 2 diabetes mellitus. Drugs 2012; 72: 249-72.
42. Tentolouris N, Voulgari C, Katsilambros N. A review of nateglinide in the management of patients with type 2 diabetes. Vasc. Health Risk Manag. 2007; 3: 797-807.
43. Hanif W, Kumar S. Nateglinide: A new rapid-acting insulinotropic agent. Expert Opin. Pharmacother. 2001; 2: 1027-31.
44. Phillippe HM, Wargo KA. Mitiglinide for type 2 diabetes treatment. Expert Opin. Pharmacother. 2013; 14: 2133-44.
45. Rosenwasser RF, Sultan S, Sutton D, Choksi R, Epstein BJ. SGLT-2 inhibitors and their potential in the treatment of diabetes. Diabetes Metab. Syndr. Obes. 2013; 6: 453-67.
46. Tahrani AA. SGLT-2 inhibitors as second-line therapy in type 2 diabetes. Lancet Diabetes Endocrinol. 2014; 2: 678-9.
47. Diamant M, Morsink LM. SGLT2 inhibitors for diabetes: Turning symptoms into therapy. Lancet 2013; 382: 917-8.
48. Nomura S, Sakamaki S, Hongu M et al. Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus. J. Med. Chem. 2010; 53: 6355-60.
49. Elkinson S, Scott LJ. Canagliflozin: First global approval. Drugs 2013; 73: 979-88.
50. Babu A. Canagliflozin for the treatment of type 2 diabetes. Drugs Today 2013; 49: 363-76.
51. Hussey EK, Dobbins RL, Stoltz RR et al. Multiple-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy overweight and obese subjects: A randomized double-blind study. J. Clin. Pharmacol. 2010; 50: 636-46.
52. Hussey EK, Clark RV, Amin DM et al. Single-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy volunteers and patients with type 2 diabetes mellitus. J. Clin. Pharmacol. 2010; 50: 623-35.
53. Kurosaki E, Ogasawara H. Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: Preclinical and clinical data. Pharmacol. Ther. 2013; 139: 51-9.
54. Imamura M, Nakanishi K, Suzuki T et al. Discovery of ipragliflozin (ASP1941): A novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus. Bioorg. Med. Chem. 2012; 20: 3263-79.
55. Veltkamp SA, Kadokura T, Krauwinkel WJ, Smulders RA. Effect of ipragliflozin (ASP1941), a novel selective sodium-dependent glucose co-transporter 2 inhibitor, on urinary glucose excretion in healthy subjects. Clin. Drug Invest. 2011; 31: 839-51.
56. Schwartz SL, Akinlade B, Klasen S, Kowalski D, Zhang W, Wilpshaar W. Safety, pharmacokinetic, and pharmacodynamic profiles of ipragliflozin (ASP1941), a novel and selective inhibitor of sodium-dependent glucose co-transporter 2, in patients with type 2 diabetes mellitus. Diabetes Technol. Ther. 2011; 13: 1219-27.
57. Fonseca VA, Ferrannini E, Wilding JP et al. Active- and placebo-controlled dose-finding study to assess the efficacy, safety, and tolerability of multiple doses of ipragliflozin in patients with type 2 diabetes mellitus. J. Diabetes Complicat. 2013; 27: 268-73.
58. Macha S, Rose P, Mattheus M et al. Pharmacokinetics, safety and tolerability of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with hepatic impairment. Diabetes Obes. Metab. 2013; 16: 118-23.
59. Kovacs CS, Seshiah V, Swallow R et al. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: A 24-week, randomized, placebo-controlled trial. Diabetes Obes. Metab. 2013; 16: 147-58.
60. Ferrannini E, Seman L, Seewaldt-Becker E, Hantel S, Pinnetti S, Woerle HJ. A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes. Diabetes Obes. Metab. 2013; 15: 721-8.
61. Green JB, Feinglos MN. Are sulfonylureas passe? Curr. Diab. Rep. 2006; 6: 373-7.
62. Aguilar-Bryan L, Bryan J. Molecular biology of adenosine triphosphate-sensitive potassium channels. Endocr. Rev. 1999; 20: 101-35.
63. Proks P, Reimann F, Green N, Gribble F, Ashcroft F. Sulfonylurea stimulation of insulin secretion. Diabetes 2002; 51 (Suppl. 3): S368-76.
64. ATP channels as molecular sensors of cellular metabolism. Nature 2006; 440: 470-6.
65. 1c in diabetes: A systematic review and meta-analysis. Diabetologia 2013; 56: 973-84.
66. Singh S, Bhat J, Wang PH. Cardiovascular effects of anti-diabetic medications in type 2 diabetes mellitus. Curr. Cardiol. Rep. 2013; 15: 327.
67. Cronet P, Petersen JF, Folmer R et al. Structure of the PPARalpha and -gamma ligand binding domain in complex with AZ 242: Ligand selectivity and agonist activation in the PPAR family. Structure 2001; 9: 699-706.
68. Ahmadian M, Suh JM, Hah N et al. PPARgamma signaling and metabolism: The good, the bad and the future. Nat. Med. 2013; 19: 557-66.
69. Lee CH, Olson P, Hevener A et al. PPARdelta regulates glucose metabolism and insulin sensitivity. Proc. Natl Acad. Sci. USA 2006; 103: 3444-9.
70. Koffarnus RL, Wargo KA, Phillippe HM. Rivoglitazone. A new thiazolidinedione for the treatment of type 2 diabetes mellitus. Ann. Pharmacother. 2013; 47: 877-85.
71. Kung J, Henry RR. Thiazolidinedione safety. Expert Opin. Drug Saf. 2012; 11: 565-79.
72. Heald M, Cawthorne MA. Dual acting and pan-PPAR activators as potential anti-diabetic therapies. Handb. Exp. Pharmacol. 2011; 203: 35-51.
73. Jani RH, Kansagra K, Jain MR, Patel H. Pharmacokinetics, safety, and tolerability of saroglitazar (ZYH1), a predominantly PPARα agonist with moderate PPARγ agonist activity in healthy human subjects. Clin. Drug Invest. 2013; 33: 809-16.
74. Bezafibrate Infarction Prevention (BIP) Study. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. Circulation 2000; 102: 21-7.
75. Chikahisa S, Tominaga K, Kawai T et al. Bezafibrate, a peroxisome proliferator-activated receptors agonist, decreases body temperature and enhances electroencephalogram delta-oscillation during sleep in mice. Endocrinology 2008; 149: 5262-71.
76. Covington P, Christopher R, Davenport M et al. Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: A randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes. Clin. Ther. 2008; 30: 499-512.
77. Devineni D, Curtin CR, Polidori D et al. Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus. J. Clin. Pharmacol. 2013; 53: 601-10.
78. Kasichayanula S, Liu X, Griffen SC, Lacreta FP, Boulton DW. Effects of rifampin and mefenamic acid on the pharmacokinetics and pharmacodynamics of dapagliflozin. Diabetes Obes. Metab. 2013; 15: 280-3.
79. Brand T, Macha S, Mattheus M, Pinnetti S, Woerle HJ. Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT-2) inhibitor, coadministered with sitagliptin in healthy volunteers. Adv. Ther. 2012; 29: 889-99.
80. Heise T, Seewaldt-Becker E, Macha S et al. Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes. Diabetes Obes. Metab. 2013; 15: 613-21.
81. Ramirez MA, Borja NL. Epalrestat. An aldose reductase inhibitor for the treatment of diabetic neuropathy. Pharmacotherapy 2008; 28: 646-55.
82. Coppack SW, Lant AF, McIntosh CS, Rodgers AV. Pharmacokinetic and pharmacodynamic studies of glibenclamide in non-insulin dependent diabetes mellitus. Br. J. Clin. Pharmacol. 1990; 29: 673-84.
83. Davis TM, Daly F, Walsh JP et al. Pharmacokinetics and pharmacodynamics of gliclazide in Caucasians and Australian Aborigines with type 2 diabetes. Br. J. Clin. Pharmacol. 2000; 49: 223-30.
84. Matsuki M, Matsuda M, Kohara K et al. Pharmacokinetics and pharmacodynamics of glimepiride in type 2 diabetic patients. Compared effects of once- versus twice-daily dosing. Endocr. J. 2007; 54: 571-6.
85. Huupponen R, Seppala P, Iisalo E. Glipizide pharmacokinetics and response in diabetics. Int. J. Clin. Pharmacol. Ther. Toxicol. 1982; 20: 417-22.
86. Kradjan WA, Kobayashi KA, Bauer LA, Horn JR, Opheim KE, Wood FJ Jr. Glipizide pharmacokinetics: Effects of age, diabetes, and multiple dosing. J. Clin. Pharmacol. 1989; 29: 1121-7.
87. von Nicolai H, Brickl R, Eschey H et al. Duration of action and pharmacokinetics of the oral antidiabetic drug gliquidone in patients with non-insulin-dependent (type 2) diabetes mellitus. Arzneimittelforschung 1997; 47: 247-52.
88. Graefe-Mody U, Retlich S, Friedrich C. Clinical pharmacokinetics and pharmacodynamics of linagliptin. Clin. Pharmacokinet. 2012; 51: 411-27.
89. Friedrich C, Glund S, Lionetti D et al. Pharmacokinetic and pharmacodynamic evaluation of linagliptin in African American patients with type 2 diabetes mellitus. Br. J. Clin. Pharmacol. 2013; 76: 445-54.
90. Hussey EK, Kapur A, O'Connor-Semmes R et al. Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus. BMC Pharmacol. Toxicol. 2013; 14: 25.
91. Zhang J, Cai LJ, Peng WX, Zhu RH, Yang J, Zhang QZ. The effects of food on the pharmacokinetics of mitiglinide tablets in healthy volunteers and a novel mass-spectrometric (UPLC-MS/MS) method for such studies. J. Clin. Pharm. Ther. 2012; 37: 95-9.
92. Weaver ML, Orwig BA, Rodriguez LC et al. Pharmacokinetics and metabolism of nateglinide in humans. Drug Metab. Dispos. 2001; 29: 415-21.
93. Budde K, Neumayer HH, Fritsche L, Sulowicz W, Stompor T, Eckland D. The pharmacokinetics of pioglitazone in patients with impaired renal function. Br. J. Clin. Pharmacol. 2003; 55: 368-74.
94. Bril V, Hirose T, Tomioka S, Buchanan R; Ranirestat Study Group. Ranirestat for the management of diabetic sensorimotor polyneuropathy. Diabetes Care 2009; 32: 1256-60.
95. Cox PJ, Ryan DA, Hollis FJ et al. Absorption, disposition, and metabolism of rosiglitazone, a potent thiazolidinedione insulin sensitizer, in humans. Drug Metab. Dispos. 2000; 28: 772-80.
96. Scott AK, Webster J, Petrie JC. Sorbinil pharmacokinetics in male and female elderly volunteers. Br. J. Clin. Pharmacol. 1987; 23: 495-7.
97. Gross AS, Bridge S, Shenfield GM. Pharmacokinetics of tolbutamide in ethnic Chinese. Br. J. Clin. Pharmacol. 1999; 47: 151-6.
98. Loi CM, Young M, Randinitis E, Vassos A, Koup JR. Clinical pharmacokinetics of troglitazone. Clin. Pharmacokinet. 1999; 37: 91-104.
99. Bergman AJ, Cote J, Yi B et al. Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor. Diabetes Care 2007; 30: 1862-4.
100. Capuano A, Sportiello L, Maiorino MI, Rossi F, Giugliano D, Esposito K. et al. Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy-focus on alogliptin. Drug Des. Devel. Ther. 2013; 7: 989-1001.